CA2668520C - Antibacterial quinoline derivatives - Google Patents

Antibacterial quinoline derivatives Download PDF

Info

Publication number
CA2668520C
CA2668520C CA2668520A CA2668520A CA2668520C CA 2668520 C CA2668520 C CA 2668520C CA 2668520 A CA2668520 A CA 2668520A CA 2668520 A CA2668520 A CA 2668520A CA 2668520 C CA2668520 C CA 2668520C
Authority
CA
Canada
Prior art keywords
alkyl
aryl
6alkyl
het
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2668520A
Other languages
English (en)
French (fr)
Other versions
CA2668520A1 (en
Inventor
Jerome Emile Georges Guillemont
Magali Madeleine Simone Motte
Koenraad Jozef Lodewijk Marcel Andries
Anil Koul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA2668520A1 publication Critical patent/CA2668520A1/en
Application granted granted Critical
Publication of CA2668520C publication Critical patent/CA2668520C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
CA2668520A 2006-12-06 2007-12-04 Antibacterial quinoline derivatives Active CA2668520C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06125521 2006-12-06
EP06125521.2 2006-12-06
PCT/EP2007/063315 WO2008068269A1 (en) 2006-12-06 2007-12-04 Antibacterial quinoline derivatives

Publications (2)

Publication Number Publication Date
CA2668520A1 CA2668520A1 (en) 2008-06-12
CA2668520C true CA2668520C (en) 2016-01-26

Family

ID=37944337

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2668520A Active CA2668520C (en) 2006-12-06 2007-12-04 Antibacterial quinoline derivatives

Country Status (29)

Country Link
US (1) US7998979B2 (enExample)
EP (1) EP2086941B1 (enExample)
JP (1) JP5356245B2 (enExample)
KR (1) KR101490221B1 (enExample)
CN (1) CN101541752B (enExample)
AR (1) AR064150A1 (enExample)
AT (1) ATE465994T1 (enExample)
AU (1) AU2007328889B2 (enExample)
BR (1) BRPI0720251B8 (enExample)
CA (1) CA2668520C (enExample)
CL (1) CL2007003516A1 (enExample)
CY (1) CY1110706T1 (enExample)
DE (1) DE602007006231D1 (enExample)
DK (1) DK2086941T3 (enExample)
ES (1) ES2344535T3 (enExample)
HR (1) HRP20100384T1 (enExample)
IL (1) IL199081A (enExample)
JO (1) JO2685B1 (enExample)
ME (1) ME01073B (enExample)
MX (1) MX2009005980A (enExample)
NO (1) NO341995B1 (enExample)
NZ (1) NZ576673A (enExample)
PL (1) PL2086941T3 (enExample)
PT (1) PT2086941E (enExample)
RS (1) RS51390B (enExample)
RU (1) RU2446159C2 (enExample)
SI (1) SI2086941T1 (enExample)
TW (1) TWI412364B (enExample)
WO (1) WO2008068269A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102110355B1 (ko) 2012-04-27 2020-05-14 얀센 파마슈티카 엔.브이. 항균성 퀴놀린 유도체
CA2869453C (en) 2012-04-27 2021-03-02 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
CN104650054B (zh) * 2013-11-25 2019-09-13 重庆医药工业研究院有限责任公司 一种抗结核菌的喹啉噻吩芳氧乙胺衍生物
US11857352B2 (en) 2016-09-06 2024-01-02 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6033389B2 (ja) * 1979-02-22 1985-08-02 日産化学工業株式会社 複素環エ−テル系フェノシキ脂肪酸誘導体、その製造法および該誘導体を含有する除草剤
US5965572A (en) 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
US6867219B2 (en) * 2001-07-31 2005-03-15 Wayne State University Antitumor agents
DK1527050T3 (da) * 2002-07-25 2010-07-19 Janssen Pharmaceutica Nv Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer
EA011277B1 (ru) 2004-01-23 2009-02-27 Янссен Фармацевтика Н.В. Производные хинолина и их применение в качестве ингибиторов микобактерий
AP2188A (en) 2004-01-23 2010-12-14 Janssen Pharmaceutica Nv Substituted quinolines and their use as mycobacterial inhibitors.
EA011572B9 (ru) * 2004-01-29 2018-01-31 Янссен Фармацевтика Н.В. Производные хинолина для применения в качестве микобактериальных ингибиторов
AU2005249231B2 (en) 2004-05-28 2010-11-11 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
RS56357B1 (sr) 2004-09-28 2017-12-29 Janssen Pharmaceutica Nv Vezujući domen bakterijske atp sintaze

Also Published As

Publication number Publication date
CN101541752A (zh) 2009-09-23
NO20092540L (no) 2009-09-07
RS51390B (sr) 2011-02-28
NO341995B1 (no) 2018-03-12
SI2086941T1 (sl) 2010-08-31
CY1110706T1 (el) 2015-06-10
HK1137428A1 (en) 2010-07-30
AR064150A1 (es) 2009-03-18
AU2007328889A1 (en) 2008-06-12
BRPI0720251A2 (pt) 2014-01-07
BRPI0720251B8 (pt) 2021-05-25
TWI412364B (zh) 2013-10-21
JO2685B1 (en) 2013-03-03
US20100063061A1 (en) 2010-03-11
HRP20100384T1 (hr) 2010-08-31
BRPI0720251B1 (pt) 2020-10-06
TW200845987A (en) 2008-12-01
CA2668520A1 (en) 2008-06-12
US7998979B2 (en) 2011-08-16
AU2007328889B2 (en) 2012-12-06
EP2086941A1 (en) 2009-08-12
RU2446159C2 (ru) 2012-03-27
ME01073B (me) 2012-10-20
PL2086941T3 (pl) 2010-10-29
ATE465994T1 (de) 2010-05-15
WO2008068269A1 (en) 2008-06-12
RU2009125525A (ru) 2011-01-20
KR101490221B1 (ko) 2015-02-05
JP2010511670A (ja) 2010-04-15
DE602007006231D1 (de) 2010-06-10
EP2086941B1 (en) 2010-04-28
KR20090087071A (ko) 2009-08-14
MX2009005980A (es) 2009-06-16
JP5356245B2 (ja) 2013-12-04
NZ576673A (en) 2011-09-30
DK2086941T3 (da) 2010-08-09
IL199081A (en) 2013-08-29
ES2344535T3 (es) 2010-08-30
PT2086941E (pt) 2010-07-14
CL2007003516A1 (es) 2008-07-11
CN101541752B (zh) 2013-07-17

Similar Documents

Publication Publication Date Title
CA2669819C (en) Antibacterial quinoline derivatives
CA2668515C (en) Antibacterial quinoline derivatives
CA2669829C (en) Antibacterial quinoline derivatives
CA2668520C (en) Antibacterial quinoline derivatives
CA2668517C (en) Antibacterial quinoline derivatives
CA2668558C (en) Antibacterial quinoline derivatives

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250604

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251106